The Role of Receptor for Advanced Glycation Endproducts (RAGE) in Infection

  • M. A. D. van Zoelen
  • A. Achouiti
  • T. van der Poll
Part of the Annual Update in Intensive Care and Emergency Medicine 2011 book series (AUICEM, volume 1)


During evolution, multicellular organisms have developed an impressive arsenal of defense and repair mechanisms to counteract threats such as infection and trauma. Such an inflammatory response begins with the detection of the potential life-threatening event by recognizing so-called danger signals. These signal molecules have been classically divided into: i) Exogenous, pathogen-associated molecular patterns (PAMPs) [1], which are conserved motifs on pathogens that are not found in higher eukaryocytes; and ii) endogenous innate danger molecules, also named damage-associated molecular patterns (DAMPs) or alarmins, which are structurally diverse proteins rapidly released by the host itself during infection or (sterile) tissue damage [2].


Idiopathic Pulmonary Fibrosis Ethyl Pyruvate Abdominal Sepsis Advanced Glycation Endproducts sRAGE Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20: 197–216PubMedCrossRefGoogle Scholar
  2. 2.
    Bianchi ME (2007) DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 81: 1–5PubMedCrossRefGoogle Scholar
  3. 3.
    Harris HE, Raucci A (2006) Alarmin(g) News about danger: Workshop on innate danger signals and HMGB1. EMBO Rep 7: 774–778PubMedGoogle Scholar
  4. 4.
    Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191–195PubMedCrossRefGoogle Scholar
  5. 5.
    Liu Y, Chen GY, Zheng P (2009) CD24-Siglec G/10 discriminates danger-from pathogen-associated molecular patterns. Trends Immunol 30: 557–561PubMedCrossRefGoogle Scholar
  6. 6.
    Liu R, Mori S, Wake H, et al (2009) Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin’s effect on binding. Acta Med Okayama 63: 203–211PubMedGoogle Scholar
  7. 7.
    Bierhaus A, Stern DM, Nawroth PP (2006) RAGE in inflammation: a new therapeutic Target? Curr Opin Investig Drugs 7: 985–991PubMedGoogle Scholar
  8. 8.
    Chavakis T, Bierhaus A, Al Fakhri N, et al (2003) The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198: 1507–1515PubMedCrossRefGoogle Scholar
  9. 9.
    Liliensiek B, Weigand MA, Bierhaus A, et al (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113: 1641–1650PubMedGoogle Scholar
  10. 10.
    Goova MT, Li J, Kislinger T, et al (2001) Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 159: 513–525PubMedCrossRefGoogle Scholar
  11. 11.
    Cataldegirmen G, Zeng S, Feirt N, et al (2005) RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 201: 473–484PubMedCrossRefGoogle Scholar
  12. 12.
    Park L, Raman KG, Lee KJ, et al (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025–1031PubMedCrossRefGoogle Scholar
  13. 13.
    Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949–955PubMedGoogle Scholar
  14. 14.
    Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331–342PubMedCrossRefGoogle Scholar
  15. 15.
    Ueno H, Matsuda T, Hashimoto S, et al (2004) Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170: 1310–1316PubMedCrossRefGoogle Scholar
  16. 16.
    Wang H, Bloom O, Zhang M, et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251PubMedCrossRefGoogle Scholar
  17. 17.
    van Zoelen MA, Laterre PF, van Veen SQ, et al (2007) Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 35: 2799–2804PubMedCrossRefGoogle Scholar
  18. 18.
    Yang H, Ochani M, Li J, et al (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101: 296–301PubMedCrossRefGoogle Scholar
  19. 19.
    Qin S, Wang H, Yuan R, et al (2006) Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 203: 1637–1642PubMedCrossRefGoogle Scholar
  20. 20.
    Suda K, Kitagawa Y, Ozawa S, et al (2006) Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 30: 1755–1762PubMedCrossRefGoogle Scholar
  21. 21.
    Wang H, Liao H, Ochani M, et al (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10: 1216–1221PubMedCrossRefGoogle Scholar
  22. 22.
    Hotchkiss RS, Nicholson DW (2006) Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6: 813–822PubMedCrossRefGoogle Scholar
  23. 23.
    Hotchkiss RS, Chang KC, Swanson PE, et al (2000) Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 1: 496–501PubMedCrossRefGoogle Scholar
  24. 24.
    Tian J, Avalos AM, Mao SY, et al (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8: 487–496PubMedCrossRefGoogle Scholar
  25. 25.
    Yang H, Hreggvidsdottir HS, Palmblad K, et al (2010) A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 107: 11942–11947PubMedCrossRefGoogle Scholar
  26. 26.
    Wittkowski H, Sturrock A, van Zoelen MA, et al (2007) Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 35: 1369–1375PubMedCrossRefGoogle Scholar
  27. 27.
    Orlova VV, Choi EY, Xie C, et al (2007) A novel pathway of HMGBl-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 26: 1129–1139PubMedCrossRefGoogle Scholar
  28. 28.
    Frommhold D, Kamphues A, Hepper I, et al (2010) RAGE and ICAM-1 Cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 116: 841–849PubMedCrossRefGoogle Scholar
  29. 29.
    Uchida T, Shirasawa M, Ware LB, et al (2006) Receptor for advanced glycation end-products is a marker of type i cell injury in acute lung injury. Am J Respir Crit Care Med 173: 1008–1015PubMedCrossRefGoogle Scholar
  30. 30.
    Cheng C, Tsuneyama K, Kominami R, et al (2005) Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 18: 1385–1396PubMedCrossRefGoogle Scholar
  31. 31.
    Englert JM, Hanford LE, Kaminski N, et al (2008) A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 172: 583–591PubMedCrossRefGoogle Scholar
  32. 32.
    Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M (2006) The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 19: 1437–1445PubMedGoogle Scholar
  33. 33.
    Buckley ST and Ehrhardt C (2010) The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010:917108PubMedCrossRefGoogle Scholar
  34. 34.
    Queisser MA, Kouri FM, Konigshoff M, et al (2008) Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am J Respir Cell Mol Biol 39: 337–345PubMedCrossRefGoogle Scholar
  35. 35.
    Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP (2006) Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 323: 475–488PubMedCrossRefGoogle Scholar
  36. 36.
    Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M (1998) Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol (Noisy-le-grand) 44: 1147–1157Google Scholar
  37. 37.
    He M, Kubo H, Ishizawa K, et al (2007) The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 293:L1427–L1436PubMedCrossRefGoogle Scholar
  38. 38.
    Reynolds PR, Schmitt RE, Kasteler SD, et al (2010) Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol 42: 545–551PubMedCrossRefGoogle Scholar
  39. 39.
    van Zoelen MA, Schouten M, de Vos AF, et al (2009) The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 182: 4349–4356PubMedCrossRefGoogle Scholar
  40. 40.
    van Zoelen MA, van der Sluijs KF, Achouiti A, et al (2009) Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 391: 265–273PubMedCrossRefGoogle Scholar
  41. 41.
    Lutterloh EC, Opal SM, Pittman DD, et al (2007) Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 11:R122PubMedCrossRefGoogle Scholar
  42. 42.
    van Zoelen MA, Schmidt AM, Florquin S, et al (2009) Receptor for advanced glycation end products facilitates host defense during Escherichia coli-induced abdominal sepsis in mice. J Infect Dis 200: 765–773PubMedCrossRefGoogle Scholar
  43. 43.
    van Zoelen MA, Achouiti A, Schmidt AM, et al (2010) Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during escherichia coli peritonitis. Crit Care Med 38: 1414–1422PubMedCrossRefGoogle Scholar
  44. 44.
    van Zoelen MA, Yang H, Florquin S, et al (2009) Role of Toll-Like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31: 280–284PubMedCrossRefGoogle Scholar
  45. 45.
    Park JS, Svetkauskaite D, He Q, et al (2004) Involvement of Toll-Like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370–7377PubMedCrossRefGoogle Scholar
  46. 46.
    Payen D, Lukaszewicz AC, Belikova I, et al (2008) Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 34: 1371–1376PubMedCrossRefGoogle Scholar
  47. 47.
    Foell D, Wittkowski H, Vogl T, Roth J (2007) S100 Proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81: 28–37PubMedCrossRefGoogle Scholar
  48. 48.
    Cole AM, Kim YH, Tahk S, et al (2001) Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. FEBS Lett 504: 5–10PubMedCrossRefGoogle Scholar
  49. 49.
    Bopp C, Hofer S, Weitz J, et al (2008) SRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 147: 79–83PubMedCrossRefGoogle Scholar
  50. 50.
    Hudson BI, Harja E, Moser B, Schmidt AM (2005) Soluble levels of receptor for advanced glycation endproducts (SRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 25: 879–882PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2011

Authors and Affiliations

  • M. A. D. van Zoelen
    • 1
  • A. Achouiti
    • 1
  • T. van der Poll
    • 1
  1. 1.Center for Experimental and Molecular Medicine and Center for Infection and ImmunityAcademic Medical CenterAmsterdamNetherlands

Personalised recommendations